EMD Serono
One Technology Place
Rockland
MA
02370
United States
Tel: 800-283-8088
Website: https://www.emdserono.com/us-en
241 articles about EMD Serono
-
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
2/29/2024
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of two new post-hoc analyses of tertiary endpoints from the MAGNIFY-MS study, a Phase IV, prospective, open-label study evaluating the efficacy and safety of MAVENCLAD® tablets in highly active relapsing multiple sclerosis.
-
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
1/22/2024
EMD Serono today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENCIO® (avelumab) maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma (UC) who do not progress on first-line chemotherapy.
-
EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District
11/14/2023
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.
-
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
10/16/2023
EMD Serono announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology Annual Meeting, October 20-24, Madrid, Spain.
-
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS
10/11/2023
Data from the ongoing Phase II open-label extension (OLE) study of evobrutinib show sustained clinical efficacy and a safety profile that remains consistent with that previously reported over five years of therapy - the longest follow-up of any Bruton’s tyrosine kinase inhibitor (BTKi) in multiple sclerosis (MS) studies Additional Phase II OLE data show significant and clinically meaningful improvements on mental health and quality of life measures in study participants with relapsing
-
EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
10/10/2023
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of new analyses from the MAVENCLAD® tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis experienced sustained reduction in serum neurofilament light chain, indicating that MAVENCLAD reduced neuronal injury over two years.
-
EMD Serono Launches New Collaboration with United Nations’ Global Initiative on Ageing to Support Caregivers
10/5/2023
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, announced a new collaboration with the United Nations’ Global Initiative on Ageing to provide a training course on critical skills for family caregivers.
-
EMD Serono Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS
2/23/2023
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term efficacy and safety data for investigational evobrutinib that continue to show a favorable safety and tolerability profile, consistent with what was seen earlier in the double-blind period (DBP) of the clinical trials.
-
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma
2/13/2023
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.
-
NCCN Announces Funding for Bladder Cancer Research Projects, in Collaboration with Pfizer and EMD Serono
11/10/2022
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced awards and funding for projects focused on improving quality of patient care and outcomes for locally advanced or metastatic bladder cancer.
-
EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment
10/26/2022
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced findings which demonstrated that annualized relapse rates remained low and Expanded Disability Status Scale scores were stable in people with relapsing multiple sclerosis treated with investigational evobrutinib through more than three and half years.
-
EMD Serono Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care
10/26/2022
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the company will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held October 26-28, 2022 in Amsterdam, the Netherlands.
-
SpringWorks, Eli Lilly, EMD Serono and Mirati released data ahead of the European Society of Medical Oncology (ESMO) 2022 Meeting in Paris.
-
Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
9/7/2022
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) compared with placebo plus CRT.
-
EMD Serono to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
9/7/2022
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced the latest research from the Company’s oncology portfolio and pipeline to be presented at this year’s European Society of Medical Oncology (ESMO) Annual Meeting, September 9-13, 2022.
-
There were multiple leadership changes in the biopharma industry, with several new chief executive officers tapped to guide companies through their next growth phases.
-
EMD Serono Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways
6/3/2022
New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology.
-
EMD Serono to Present Latest Research From Oncology Portfolio at ASCO 2022
5/26/2022
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting.
-
EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
3/31/2022
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced 13 abstracts from the Company’s multiple sclerosis portfolio will be presented at the 2022 American Academy of Neurology Annual Meeting, being held April 2-7.
-
New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favorable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression
2/24/2022
EMD Serono announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® tablets had more favorable relapse outcomes and longer time to switch to another disease modifying therapy compared to the oral DMTs fingolimod, dimethyl fumarate and teriflunomide in relapsing multiple sclerosis patients.